关注
Jean-Charles Soria
Jean-Charles Soria
Amgen R&D
在 amgen.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Pembrolizumab for the treatment of non–small-cell lung cancer
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
65032015
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ...
Nature 515 (7528), 563-567, 2014
54132014
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ...
New England journal of medicine 378 (2), 113-125, 2018
45252018
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
45142018
DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy
KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ...
New England Journal of Medicine 355 (10), 983-991, 2006
23432006
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ...
New England Journal of Medicine 382 (1), 41-50, 2020
21632020
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ...
European journal of cancer 54, 139-148, 2016
21092016
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
14812012
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
13092017
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
12282017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
12232017
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ...
Nature reviews Clinical oncology 13 (8), 473-486, 2016
10562016
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ...
Annals of Oncology 27 (4), 559-574, 2016
10182016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ...
The Lancet 387 (10026), 1415-1426, 2016
9542016
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ...
The Lancet Oncology 19 (9), 1180-1191, 2018
9482018
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
JM Pitt, A Marabelle, A Eggermont, JC Soria, G Kroemer, L Zitvogel
Annals of Oncology 27 (8), 1482-1492, 2016
9222016
Management of non-small-cell lung cancer: recent developments
M Reck, DF Heigener, T Mok, JC Soria, KF Rabe
The Lancet 382 (9893), 709-719, 2013
8402013
Rociletinib in EGFR-mutated non–small-cell lung cancer
LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ...
New England Journal of Medicine 372 (18), 1700-1709, 2015
8252015
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ...
Journal of Clinical Oncology 36 (1), 7-13, 2018
8182018
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 …
PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ...
Journal of Clinical Oncology 37 (4), 318-327, 2019
7692019
系统目前无法执行此操作,请稍后再试。
文章 1–20